Embedded Safety & Security Summit (ESSS) 2021 Announces Speaker Line-up for Virtual Conference
11.5.2021 15:00:00 EEST | Business Wire | Press release
The Embedded Safety & Security Summit (ESSS) today announced its first set of speakers for the inaugural virtual event, scheduled for June 17, 2021. Based on LDRA’s long-running annual conference, ESSS brings together embedded technology enthusiasts, industry thought leaders and regulators worldwide to share emerging trends, best practices, technical deep dive, and practical examples on empowering the development of safe and secure embedded systems.
In addition to Ian Hennell, Operations Director of LDRA, confirmed speakers and their presentations include:
Technical Panel : Next-gen Technologies: Safety and Security Implications
Dr Nigel Tracey, Vice President – RTA Solutions, ETAS, Germany
Suresh Kumar R, CTO CCS India & Digital Incubators, GE-Healthcare, India
Bill. St. Clair, Director – US Operations, LDRA, USA
Shinto Joseph, Director – South East Asia Operations, LDRA, India
Industrial Cybersecurity System (ICS) defenses what is next?
Felipe Sabino Costa, LATAM Industrial Cybersecurity (IACS) Expert, Brazil
MISRA C in the ISO 26262 Context
Andrew Banks, Chairman of the MISRA C Working Group, Technical Specialist, LDRA, UK
UNECE WP.29 Regulations for Automotive Security – A View from India
Khushwant Pawar, Head, Cybersecurity Solutions – Mobility, ETAS, India
Balancing the Load of a Safety Critical Multi Core System
Mohamed Zuhair, Electronics Engineer, TASKING, India
Challenges in Testing & Certification of AI-ML based systems in Aerospace
Shashi Kumar P, Principal Engineer – Certification, Honeywell Aerospace, India
Koilpillai George, Chief Engineers – Software, Honeywell Aerospace, India
Do All Your Build Tools Need To Be Qualified?
Chris Tapp, Chairman of the MISRA C++ Working Group, Technical Specialist, LDRA, UK
Hardware Enablers for Security in Industrial IoT
Mini TT, Principal Engineer, ABB, India
FACE Standard Verification and Validation for Safety Environments
Ehsan Salehi, Field Application Manager & FACE™ VA, LDRA, USA
System Safety Enhancement using Fault Tolerant Design
Manju Maheve, System Safety Engineer, Collins Aerospace, India
Priya Peter, System Safety and Reliability Engineer, Collins Aerospace, India
Verification Activities to be Considered for Achieving IEC 62304 Compliance
Anil Kumar N.G, Sr. Technical Manager, LDRA, India
“The deep-dive technical sessions from industry experts across the aerospace & defence, automotive, industrial, and medical domain offer an ideal mix of insights into the growing significance of implementing safe and secure practices and technologies in embedded systems,” Hennell said. “While we’ll miss being in-person this year, we expect even more within the embedded community will benefit from these valuable virtual sessions and the networking opportunities that everyone has grown to expect at ESSS.”
The virtual conference platform will offer industry-focused tracks and allow myriad networking opportunities for attendees and speakers with chat room features and live Q&As. For more information and to register for free, please visit https://www.embedded-safety-security.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005073/en/
Contact information
Kelly Wanlass, HCI Marketing and Communications, Inc., Media Relations
Tel: +1 (801) 602-4723, Email: kelly@hci-marketing.com
Mark James, LDRA, Marketing Manager
Tel: +44 (0) 151 649 9300, Email: mark.james@ldra.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom